NATCO Pharma updates on legal proceedings on Risdiplam launch in India

NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court

Delhi becomes 35th state/UT to implement AB PM-JAY

Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs

Metropolis to acquire Dehradun’s Ahujas’ Pathology & Imaging Centre for Rs. 35.01 Cr

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases

Gland Pharma receives approval for Acetaminophen Injection

The company expects to launch this product through its marketing partner in the near future

SPARC announces submission of IND Application for SBO-154 to USFDA

The IND application supports the next phase of development of SBO-154

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease